Jennison Associates LLC Vertex Pharmaceuticals Inc Transaction History

Jennison Associates LLC

$149 Billion
Q1 2024

A detailed history of Jennison Associates LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Jennison Associates LLC holds 4,782,374 shares of VRTX stock, worth $2.18 Billion. This represents 1.34% of its overall portfolio holdings.

Number of Shares

4,782,374

Previous 3,944,913 21.23%

Holding current value

$2.18 Billion

Previous $1.61 Billion 24.54%

% of portfolio

1.34%

Previous 1.21%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$407.69 - $446.08 $341 Million - $374 Million	837,461 Added 21.23%	4,782,374 $2 Billion
Q4 2023 Feb 01, 2024	BUY	$343.0 - $410.68 $50.5 Million - $60.5 Million	147,248 Added 3.88%	3,944,913 $1.61 Billion
Q3 2023 Oct 31, 2023	SELL	$338.18 - $362.46 $2.7 Million - $2.89 Million	-7,976 Reduced 0.21%	3,797,665 $1.32 Billion
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $243 Million - $272 Million	-774,160 Reduced 16.9%	3,805,641 $1.34 Billion
Q1 2023 Apr 26, 2023	SELL	$283.23 - $323.1 $152 Million - $173 Million	-535,739 Reduced 10.47%	4,579,801 $1.44 Billion

Q4 2022 Feb 09, 2023	BUY	$285.76 - $321.48 $103 Million - $116 Million	359,719 Added 7.56%	5,115,540 $1.48 Billion
Q3 2022 Nov 01, 2022	BUY	$273.83 - $305.53 $817 Million - $911 Million	2,983,253 Added 168.3%	4,755,821 $1.38 Billion
Q2 2022 Aug 02, 2022	BUY	$234.96 - $292.55 $334 Million - $416 Million	1,422,478 Added 406.32%	1,772,568 $499 Million
Q1 2022 May 11, 2022	SELL	$221.42 - $260.97 $95.9 Million - $113 Million	-433,299 Reduced 55.31%	350,090 $91.4 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $8.14 Million - $10.3 Million	-45,970 Reduced 5.54%	783,389 $172 Million
Q3 2021 Nov 09, 2021	BUY	$181.39 - $202.99 $6.81 Million - $7.62 Million	37,531 Added 4.74%	829,359 $150 Million
Q2 2021 Aug 12, 2021	BUY	$187.49 - $221.1 $14.3 Million - $16.8 Million	76,039 Added 10.62%	791,828 $160 Million
Q1 2021 May 11, 2021	SELL	$207.02 - $241.31 $628 Million - $732 Million	-3,033,565 Reduced 80.91%	715,789 $154 Million
Q4 2020 Feb 05, 2021	BUY	$207.01 - $276.09 $29 Million - $38.7 Million	140,270 Added 3.89%	3,749,354 $886 Million
Q3 2020 Nov 04, 2020	SELL	$255.65 - $303.1 $207 Million - $245 Million	-809,397 Reduced 18.32%	3,609,084 $982 Million
Q2 2020 Aug 06, 2020	BUY	$225.48 - $295.8 $12.8 Million - $16.8 Million	56,726 Added 1.3%	4,418,481 $1.28 Billion
Q1 2020 May 06, 2020	BUY	$199.77 - $247.81 $158 Million - $196 Million	790,506 Added 22.14%	4,361,755 $1.04 Billion
Q4 2019 Feb 07, 2020	SELL	$166.71 - $223.91 $401 Million - $539 Million	-2,406,492 Reduced 40.26%	3,571,249 $782 Million
Q3 2019 Nov 08, 2019	SELL	$166.23 - $187.09 $61 Million - $68.6 Million	-366,718 Reduced 5.78%	5,977,741 $1.01 Billion
Q2 2019 Aug 06, 2019	SELL	$164.61 - $190.37 $75.1 Million - $86.8 Million	-455,977 Reduced 6.71%	6,344,459 $0
Q1 2019 May 10, 2019	SELL	$163.73 - $194.7 $23.1 Million - $27.5 Million	-141,185 Reduced 2.03%	6,800,436 $1.25 Billion
Q4 2018 Feb 06, 2019	BUY	$151.91 - $192.21 $112 Million - $142 Million	739,128 Added 11.92%	6,941,621 $1.15 Billion
Q3 2018 Nov 08, 2018	BUY	$167.73 - $192.74 $191 Million - $220 Million	1,139,486 Added 22.51%	6,202,493 $1.2 Billion
Q2 2018 Aug 02, 2018	SELL	$145.72 - $169.96 $250 Million - $291 Million	-1,712,321 Reduced 25.27%	5,063,007 $861 Million
Q1 2018 Apr 20, 2018	BUY	$151.6 - $177.13 $188 Million - $219 Million	1,237,421 Added 22.34%	6,775,328 $1.1 Billion
Q4 2017 Jan 25, 2018	SELL	$137.28 - $155.55 $65.9 Million - $74.6 Million	-479,859 Reduced 7.97%	5,537,907 $830 Million
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $891 Million - $976 Million	6,017,766	6,017,766 $915 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.

Account

Jennison Associates LLC Vertex Pharmaceuticals Inc Transaction History